FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4200291052> ?p ?o ?g. }

• W4200291052 endingPage "103455" @default.
• W4200291052 startingPage "103455" @default.
• W4200291052 abstract "Several concerns exist on the immunogenicity of SARS-CoV-2 vaccines in multiple sclerosis (MS) subjects due to their immunomodulating disease modifying therapies (DMTs). Here we report a comparison of the humoral response to BNT162b2-mRNA coronavirus (COVID)-19 vaccine and the immunological phenotype in a cohort of 125 MS subjects undergoing different DMTs, with no history of SARS-CoV-2 infection.We collected serum and blood samples at the first day of vaccine (T0) and 21 days after the second vaccine dose (T1) from 125 MS subjects, undergoing eight different DMTs. Sera were tested using the Elecsys anti-SARS-CoV-2-IgG assay for the detection of IgG antibodies to SARS-CoV-2 spike protein. The anti-spike IgG titres from MS subjects were compared with 24 age- and sex-matched healthy controls (HC). Percentage and absolute number of B and T lymphocytes were evaluated by cytofluorimetric analysis in the same study cohort.When compared with SARS-CoV-2 IgG levels in HC (n = 24, median 1089 (IQR 652.5-1625) U/mL), we observed an increased secretion of SARS-CoV-2 IgG in interferon-beta 1a (IFN)-treated MS subjects (n = 22, median 1916 (IQR 1024-2879) U/mL) and an impaired humoral response in MS subjects undergoing cladribine (CLAD) (n = 10, median 396.9 (IQR 37.52-790.9) U/mL), fingolimod (FTY) (n = 19, median 7.9 (IQR 4.8-147.6) U/mL) and ocrelizumab (OCRE) (n = 15, median 0.67 (IQR 0.4-5.9) U/mL) treatment. Moreover, analysis of geometric mean titre ratio (GMTR) between different DMT's groups of MS subjects revealed that, when compared with IFN-treated MS subjects, intrinsic antibody production was impaired in teriflunomide (TERI)-, natalizumab (NAT)-, CLAD-, FTY- and OCRE-, while preserved in DMF- and GA-treated MS subjects.Humoral response to BNT162b2-mRNA-vaccine was increased in IFN-treated MS subjects while clearly blunted in those under CLAD, FTY and OCRE treatment. This suggests that the DMTs could have a key role in the protection from SARS-CoV-2 related disease and complication in MS subjects, underlying a novel aspect that should be considered in the selection of the most appropriate therapy under COVID-19 pandemic." @default.
• W4200291052 created "2021-12-31" @default.
• W4200291052 creator A5002183392 @default.
• W4200291052 creator A5006122581 @default.
• W4200291052 creator A5006325012 @default.
• W4200291052 creator A5011195729 @default.
• W4200291052 creator A5013748934 @default.
• W4200291052 creator A5015219338 @default.
• W4200291052 creator A5023708810 @default.
• W4200291052 creator A5029087975 @default.
• W4200291052 creator A5034819480 @default.
• W4200291052 creator A5036487469 @default.
• W4200291052 creator A5038256946 @default.
• W4200291052 creator A5039349581 @default.
• W4200291052 creator A5045607668 @default.
• W4200291052 creator A5052571685 @default.
• W4200291052 creator A5053378187 @default.
• W4200291052 creator A5067191204 @default.
• W4200291052 creator A5069091830 @default.
• W4200291052 creator A5072191302 @default.
• W4200291052 creator A5082323154 @default.
• W4200291052 creator A5086238173 @default.
• W4200291052 creator A5088993245 @default.
• W4200291052 date "2022-02-01" @default.
• W4200291052 modified "2023-09-28" @default.
• W4200291052 title "Interferon Beta-1a treatment promotes SARS-CoV-2 mRNA vaccine response in multiple sclerosis subjects" @default.
• W4200291052 cites W2049566645 @default.
• W4200291052 cites W2114494341 @default.
• W4200291052 cites W2771951908 @default.
• W4200291052 cites W2802953285 @default.
• W4200291052 cites W2882999132 @default.
• W4200291052 cites W3007643904 @default.
• W4200291052 cites W3042308502 @default.
• W4200291052 cites W3045825841 @default.
• W4200291052 cites W3090844627 @default.
• W4200291052 cites W3091444236 @default.
• W4200291052 cites W3093367571 @default.
• W4200291052 cites W3111255098 @default.
• W4200291052 cites W3121831652 @default.
• W4200291052 cites W3132354629 @default.
• W4200291052 cites W3153281865 @default.
• W4200291052 cites W3155816660 @default.
• W4200291052 cites W3168632992 @default.
• W4200291052 cites W3177818710 @default.
• W4200291052 cites W3199233027 @default.
• W4200291052 doi "https://doi.org/10.1016/j.msard.2021.103455" @default.
• W4200291052 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34929455" @default.
• W4200291052 hasPublicationYear "2022" @default.
• W4200291052 type Work @default.
• W4200291052 citedByCount "10" @default.
• W4200291052 countsByYear W42002910522022 @default.
• W4200291052 countsByYear W42002910522023 @default.
• W4200291052 crossrefType "journal-article" @default.
• W4200291052 hasAuthorship W4200291052A5002183392 @default.
• W4200291052 hasAuthorship W4200291052A5006122581 @default.
• W4200291052 hasAuthorship W4200291052A5006325012 @default.
• W4200291052 hasAuthorship W4200291052A5011195729 @default.
• W4200291052 hasAuthorship W4200291052A5013748934 @default.
• W4200291052 hasAuthorship W4200291052A5015219338 @default.
• W4200291052 hasAuthorship W4200291052A5023708810 @default.
• W4200291052 hasAuthorship W4200291052A5029087975 @default.
• W4200291052 hasAuthorship W4200291052A5034819480 @default.
• W4200291052 hasAuthorship W4200291052A5036487469 @default.
• W4200291052 hasAuthorship W4200291052A5038256946 @default.
• W4200291052 hasAuthorship W4200291052A5039349581 @default.
• W4200291052 hasAuthorship W4200291052A5045607668 @default.
• W4200291052 hasAuthorship W4200291052A5052571685 @default.
• W4200291052 hasAuthorship W4200291052A5053378187 @default.
• W4200291052 hasAuthorship W4200291052A5067191204 @default.
• W4200291052 hasAuthorship W4200291052A5069091830 @default.
• W4200291052 hasAuthorship W4200291052A5072191302 @default.
• W4200291052 hasAuthorship W4200291052A5082323154 @default.
• W4200291052 hasAuthorship W4200291052A5086238173 @default.
• W4200291052 hasAuthorship W4200291052A5088993245 @default.
• W4200291052 hasBestOaLocation W42002910522 @default.
• W4200291052 hasConcept C126322002 @default.
• W4200291052 hasConcept C159654299 @default.
• W4200291052 hasConcept C203014093 @default.
• W4200291052 hasConcept C2776036978 @default.
• W4200291052 hasConcept C2780640218 @default.
• W4200291052 hasConcept C2780868878 @default.
• W4200291052 hasConcept C2908698914 @default.
• W4200291052 hasConcept C2994247566 @default.
• W4200291052 hasConcept C71924100 @default.
• W4200291052 hasConcept C72563966 @default.
• W4200291052 hasConcept C90924648 @default.
• W4200291052 hasConceptScore W4200291052C126322002 @default.
• W4200291052 hasConceptScore W4200291052C159654299 @default.
• W4200291052 hasConceptScore W4200291052C203014093 @default.
• W4200291052 hasConceptScore W4200291052C2776036978 @default.
• W4200291052 hasConceptScore W4200291052C2780640218 @default.
• W4200291052 hasConceptScore W4200291052C2780868878 @default.
• W4200291052 hasConceptScore W4200291052C2908698914 @default.
• W4200291052 hasConceptScore W4200291052C2994247566 @default.
• W4200291052 hasConceptScore W4200291052C71924100 @default.
• W4200291052 hasConceptScore W4200291052C72563966 @default.
• W4200291052 hasConceptScore W4200291052C90924648 @default.
• W4200291052 hasFunder F4320309746 @default.

• next